| __timestamp | Apellis Pharmaceuticals, Inc. | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 8246000000 |
| Thursday, January 1, 2015 | 6356782 | 9232000000 |
| Friday, January 1, 2016 | 4303743 | 9366000000 |
| Sunday, January 1, 2017 | 10463151 | 9672000000 |
| Monday, January 1, 2018 | 22639184 | 9915000000 |
| Tuesday, January 1, 2019 | 67046483 | 11402000000 |
| Wednesday, January 1, 2020 | 139401000 | 11456000000 |
| Friday, January 1, 2021 | 176771000 | 10975000000 |
| Saturday, January 1, 2022 | 277163000 | 8372000000 |
| Sunday, January 1, 2023 | 500815000 | 9385000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of GSK plc and Apellis Pharmaceuticals, Inc. over the past decade. GSK, a global healthcare giant, consistently reported SG&A expenses exceeding $9 billion annually, peaking at $11.5 billion in 2020. In contrast, Apellis, a burgeoning biotech firm, saw its SG&A expenses grow from a modest $2.9 million in 2014 to a substantial $500 million by 2023, marking a staggering increase of over 17,000%. This dramatic rise reflects Apellis's aggressive expansion and investment in its operational capabilities. Meanwhile, GSK's expenses remained relatively stable, highlighting its established market presence and operational maturity. This comparison underscores the diverse strategies employed by established and emerging players in the pharmaceutical sector.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Amgen Inc. vs GSK plc Trends and Insights
Breaking Down SG&A Expenses: GSK plc vs Biogen Inc.
SG&A Efficiency Analysis: Comparing GSK plc and Summit Therapeutics Inc.
Cost Management Insights: SG&A Expenses for GSK plc and MorphoSys AG
Selling, General, and Administrative Costs: GSK plc vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: GSK plc vs BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Biogen Inc. vs Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Apellis Pharmaceuticals, Inc.
Lantheus Holdings, Inc. or Apellis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?